What drove ALNEV.PA stock volume today?

Volume rose to **14.53M** shares on 24 Feb 2026 without a company release, indicating retail-driven trading and short-term speculative flows rather than confirmed fundamental news.

What is Meyka AI’s grade for ALNEV.PA?

Meyka AI rates ALNEV.PA **62.72/100 (Grade B, HOLD)**. The grade factors in benchmark and sector comparisons, financial growth, key metrics, and analyst inputs; it is informational, not investment advice.

What are the main risks for Neovacs (ALNEV.PA)?

Primary risks include tiny market cap (**€858.00**), negative EPS (**-221.36**), low liquidity, potential dilution, and binary clinical trial outcomes that can swing the share price dramatically.

Does Meyka AI provide a price forecast for ALNEV.PA?

Yes. Meyka AI's forecast model projects a **3-month target of €0.0050** and a **12-month base case of €0.0200**, but these are model-based projections and not guarantees.

EU Stocks

ALNEV.PA Neovacs S.A. EURONEXT 24 Feb 2026: €0.0018, 14.53M shares traded

ByDanny Kontos February 25, 2026February 25, 2026

ALNEV.PA stock closed the EURONEXT session at €0.0018 on 24 Feb 2026 after 14,525,422 shares changed hands, marking Neovacs S.A. among the market’s most active small caps today. The share rose 5.88% from the prior close of €0.0017 on heavy intraday turnover, highlighting speculative liquidity and extreme volatility in the Biotechnology sector. Market Closed on EURONEXT, and intraday flows were well above the 3-month average, signaling short-term trader interest rather than fresh fundamental news.